Integrated Filing — IndAS



General information about company

Scrip Code 544319
NSE Symbol SENORES
MSEI Symbol NOTLISTED
ISIN INE0RB801010
Name of company SENORES PHARMACEUTICALS LIMITED
Type of company Main Board
Class of security Equity
Date of start of financial year 01-04-2025
Date of end of financial year 31-03-2026
Date of board meeting when results were approved 14-05-2026
Date on which prior intimation of the meeting for considering financial results was informed to the exchange 08-05-2026
Description of presentation currency INR
Level of rounding used in financial results Lakhs
Reporting Type Quarterly
Reporting Quarter Fourth quarter
Nature of report standalone or consolidated Standalone
Whether results are audited or unaudited for the quarter ended Audited
Whether results are audited or unaudited for the Year to date for current period ended/year ended Audited
Segment Reporting Single segment
Description of single segment Pharmaceuticals
Start date and time of board meeting 14-05-2026   11:45:00
End date and time of board meeting 14-05-2026   14:00:00
Whether cash flow statement is applicable on company Yes
Type of cash flow statement Cash Flow Indirect
Declaration of unmodified opinion or statement on impact of audit qualification Declaration of unmodified opinion
Whether the company has any related party? Yes
Whether the company has entered into any Related Party transaction during the selected half year for which it wants to submit disclosure? Yes
(I) We declare that the acceptance of fixed deposits by the bans/Non-Banking Finance Company are at the terms uniformly applicable/offered to all shareholders/public NA
(II) We declare that the scheduled commercial bank, as per RBI circular RBI/DBR/2015-16/19 dated March 03, 2016, has allowed additional interest of one per cent per annum, over and above the rate of interest mentioned in the schedule of interest rates on savings or a term deposits of banks staff and their exclusive associations as well as on deposits of Chairman, Chairman & Managing Director, Executive Director or such other Executives appointed for a fixed tenure. NA
Whether the company is a high value debt listed entity according to regulation 15 (1A)? No
(a) If answer to above question is Yes, whether complying with proviso to regulation 23 (9), i.e., submitting RPT disclosures on the day of results publication?
(b) If answer to above question is No, please explain the reason for not complying.
Whether the updated Related Party Transactions (RPT) Policy (in compliance with Reg. 23 of SEBI LODR) has been uploaded on the website of the Company? Yes
Latest Date on which RPT policy is updated 28-03-2026
Indicate Company website link for updated RPT policy of the Company https://senorespharma.com/policies/
Whether statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc. is applicable to the company for the current quarter? Yes
No. of times funds raised during the quarter 2
Whether the disclosure for the Default on Loans and Debt Securities is applicable to the entity? No
Not Applicable



Financial Results Ind-AS

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-01-2026 01-04-2025
B Date of end of reporting period 31-03-2026 31-03-2026
C Whether results are audited or unaudited Audited Audited
D Nature of report standalone or consolidated Standalone Standalone
1 Income
Revenue from operations 3,681.00 10,609.00
Other income 2,219.00 6,635.00
Total income 5,900.00 17,244.00
2 Expenses
(a) Cost of materials consumed 1,836.00 2,455.00
(b) Purchases of stock-in-trade 510.00 3,042.00
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade 6.00 (30.00)
(d) Employee benefit expense 1,112.00 3,878.00
(e) Finance costs 189.00 698.00
(f) Depreciation, depletion and amortisation expense 413.00 1,323.00
(f) Other Expenses
1 Other Expenses 565.00 3,132.00
Total other expenses 565.00 3,132.00
Total expenses 4,631.00 14,498.00
3 Total profit before exceptional items and tax 1,269.00 2,746.00
4 Exceptional items 0.00 0.00
5 Total profit before tax 1,269.00 2,746.00
6 Tax expense
7 Current tax 648.00 845.00
8 Deferred tax (227.00) (124.00)
9 Total tax expenses 421.00 721.00
10 Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement 0.00 0.00
11 Net Profit Loss for the period from continuing operations 848.00 2,025.00
12 Profit (loss) from discontinued operations before tax 0.00 0.00
13 Tax expense of discontinued operations 0.00 0.00
14 Net profit (loss) from discontinued operation after tax 0.00 0.00
15 Share of profit (loss) of associates and joint ventures accounted for using equity method 0.00 0.00
16 Total profit (loss) for period 848.00 2,025.00
17 Other comprehensive income net of taxes 6.00 (1.00)
18 Total Comprehensive Income for the period 854.00 2,024.00
19 Total profit or loss, attributable to
Profit or loss, attributable to owners of parent
Total profit or loss, attributable to non-controlling interests
20 Total Comprehensive income for the period attributable to
Comprehensive income for the period attributable to owners of parent
Total comprehensive income for the period attributable to owners of parent non-controlling interests
21 Details of equity share capital
Paid-up equity share capital 4,605.00 4,605.00
Face value of equity share capital 10 10
27 Details of debt securities
22 Reserves excluding revaluation reserve 66,191.00
23 Earnings per share
i Earnings per equity share for continuing operations
Basic earnings (loss) per share from continuing operations 1.84 4.4
Diluted earnings (loss) per share from continuing operations 1.84 4.4
ii Earnings per equity share for discontinued operations
Basic earnings (loss) per share from discontinued operations 0 0
Diluted earnings (loss) per share from discontinued operations 0 0
ii Earnings per equity share
Basic earnings (loss) per share from continuing and discontinued operations 1.84 4.4
Diluted earnings (loss) per share from continuing and discontinued operations 1.84 4.4
24 Debt equity ratio
25 Debt service coverage ratio
26 Interest service coverage ratio
27 Disclosure of notes on financial results



Remarks

Debt equity ratio
Debt service coverage ratio
Interest service coverage ratio


Statement of Asset and Liabilities

Amount in (Lakhs)

Particulars Year ended (dd-mm-yyyy)
Date of start of reporting period 01-04-2025
Date of end of reporting period 31-03-2026
Whether results are audited or unaudited Audited
Nature of report standalone or consolidated Standalone
Assets
1 Non-current assets
Property, plant and equipment 9,792.00
Capital work-in-progress 854.00
Investment property 0.00
Goodwill 0.00
Other intangible assets 1.00
Intangible assets under development 376.00
Biological assets other than bearer plants 0.00
Investments accounted for using equity method 0.00
Non-current financial assets
Non-current investments 15,448.00
Trade receivables, non-current 0.00
Loans, non-current 36,098.00
Other non-current financial assets
1 Other Financial Assets 370.00
Total of other non-current financial assets 370.00
Total non-current financial assets 51,916.00
Deferred tax assets (net) 154.00
Other non-current assets
1 Other non-current assets 134.00
Total of other non-current assets 134.00
Total non-current assets 63,227.00
2 Current assets
Inventories 975.00
Current financial asset
Current investments 0.00
Trade receivables, current 7,646.00
Cash and cash equivalents 3,222.00
Bank balance other than cash and cash equivalents 11,379.00
Loans, current 0.00
Other current financial assets
Total of other current financial assets 0.00
Total current financial assets 22,247.00
Current tax assets (net) 0.00
Other current assets
1 Other current assets 2,342.00
Total of other current assets 2,342.00
Total current assets 25,564.00
3 Non-current assets classified as held for sale 0.00
4 Regulatory deferral account debit balances and related deferred tax Assets 0.00
Total assets 88,791.00
Equity and liabilities
1 Equity
Equity attributable to owners of parent
Equity share capital 4,605.00
Other equity 70,385.00
Total equity attributable to owners of parent 74,990.00
Non controlling interest
Total equity 74,990.00
2 Liabilities
Non-current liabilities
Non-current financial liabilities
Borrowings, non-current 5,177.00
Trade payables, non-current
(A) Total outstanding dues of micro enterprises and small enterprises 0.00
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 0.00
Total Trade payable 0.00
Other non-current financial liabilities
1 Lease Liabilities 1,204.00
Total of other non-current financial liabilities 1,204.00
Total non-current financial liabilities 6,381.00
Provisions, non-current 464.00
Deferred tax liabilities (net) 0.00
Deferred government grants, Non-current 0.00
Other non-current liabilities
Total of other non-current liabilities
Total non-current liabilities 6,845.00
Current liabilities
Current financial liabilities
Borrowings, current 1,974.00
Trade payables, current
(A) Total outstanding dues of micro enterprises and small enterprises 218.00
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 2,925.00
Total Trade payable 3,143.00
Other current financial liabilities
1 Other current financial liabilities 1,002.00
2 Lease Liabilities 182.00
Total of other current financial liabilities 1,184.00
Total current financial liabilities 6,301.00
Other current liabilities 141.00
1 Other current liabilities 141.00
Total of other current liabilities 141.00
Provisions, current 50.00
Current tax liabilities (Net) 464.00
Deferred government grants, Current 0.00
Total current liabilities 6,956.00
3 Liabilities directly associated with assets in disposal group classified as held for sale
4 Regulatory deferral account credit balances and related deferred tax liability
Total liabilities 13,801.00
Total equity and liabilites 88,791.00
Disclosure of notes on assets and liabilities



Format for Reporting Segment wise Revenue, Results and Capital Employed along with the company results

Amount in (Lakhs)

Particulars 3 months/ 6 month ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period 01-01-2026 01-04-2025
Date of end of reporting period 31-03-2026 31-03-2026
Whether results are audited or unaudited Audited Audited
Nature of report standalone or consolidated Standalone Standalone
1 Segment Revenue (Income)
(net sale/income from each segment should be disclosed)
Total Segment Revenue
Less: Inter segment revenue
Revenue from operations
2 Segment Result
Profit (+) / Loss (-) before tax and interest from each segment
Total Profit before tax
i. Finance cost
ii. Other Unallocable Expenditure net off Unallocable income
Profit before tax
3 (Segment Asset - Segment Liabilities)
Segment Asset
Total Segment Asset
Un-allocable Assets null null
Net Segment Asset null null
4 Segment Liabilities
Segment Liabilities
Total Segment Liabilities
Un-allocable Liabilities null null
Net Segment Liabilities null null
Disclosure of notes on segments



Other Comprehensive Income

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-01-2026 01-04-2025
B Date of end of reporting period 31-03-2026 31-03-2026
C Whether results are audited or unaudited Audited Audited
D Nature of report standalone or consolidated Standalone Standalone
Other comprehensive income [Abstract]
1 Amount of items that will not be reclassified to profit and loss
1 Remeasurement of defined benefit obligations 9.00 (1.00)
Total Amount of items that will not be reclassified to profit and loss 9.00 (1.00)
2 Income tax relating to items that will not be reclassified to profit or loss 3.00 0.00
3 Amount of items that will be reclassified to profit and loss
Total Amount of items that will be reclassified to profit and loss
4 Income tax relating to items that will be reclassified to profit or loss 0.00 0.00
5 Total Other comprehensive income 6.00 (1.00)



Cash flow statement, indirect

Amount in (Lakhs)

Particulars Year ended (dd-mm-yyyy)
A Date of start of reporting period 01-04-2025
B Date of end of reporting period 31-03-2026
C Whether results are audited or unaudited Audited
D Nature of report standalone or consolidated Standalone
Statement of cash flows
Cash flows from used in operating activities
Profit before tax 2,746.00
Adjustments for reconcile profit (loss)
Adjustments for finance costs 613.00
Adjustments for decrease (increase) in inventories (109.00)
Adjustments for decrease (increase) in trade receivables, current (5,077.00)
Adjustments for decrease (increase) in trade receivables, non-current 0.00
Adjustments for decrease (increase) in other current assets (627.00)
Adjustments for decrease (increase) in other non-current assets (88.00)
Adjustments for other financial assets, non-current 25.00
Adjustments for other financial assets, current 85.00
Adjustments for other bank balances 0.00
Adjustments for increase (decrease) in trade payables, current 1,833.00
Adjustments for increase (decrease) in trade payables, non-current 0.00
Adjustments for increase (decrease) in other current liabilities (68.00)
Adjustments for increase (decrease) in other non-current liabilities 0.00
Adjustments for depreciation and amortisation expense 1,323.00
Adjustments for impairment loss reversal of impairment loss recognised in profit or loss 0.00
Adjustments for provisions, current (30.00)
Adjustments for provisions, non-current 312.00
Adjustments for other financial liabilities, current 510.00
Adjustments for other financial liabilities, non-current 0.00
Adjustments for unrealised foreign exchange losses gains 0.00
Adjustments for dividend income 0.00
Adjustments for interest income 3,743.00
Adjustments for share-based payments 0.00
Adjustments for fair value losses (gains) 0.00
Adjustments for undistributed profits of associates 0.00
Other adjustments for which cash effects are investing or financing cash flow 0.00
Other adjustments to reconcile profit (loss) 0.00
Other adjustments for non-cash items 85.00
Share of profit and loss from partnership firm or association of persons or limited liability partnerships 0.00
Total adjustments for reconcile profit (loss) (4,956.00)
Net cash flows from (used in) operations (2,210.00)
Dividends received 0.00
Interest paid 0.00
Interest received 0.00
Income taxes paid (refund) 478.00
Other inflows (outflows) of cash 0.00
Net cash flows from (used in) operating activities (2,688.00)
Cash flows from used in investing activities
Cash flows from losing control of subsidiaries or other businesses 0.00
Cash flows used in obtaining control of subsidiaries or other businesses 0.00
Other cash receipts from sales of equity or debt instruments of other entities 0.00
Other cash payments to acquire equity or debt instruments of other entities 4,664.00
Other cash receipts from sales of interests in joint ventures 0.00
Other cash payments to acquire interests in joint ventures 0.00
Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships 0.00
Cash payment for investment in partnership firm or association of persons or limited liability partnerships 0.00
Proceeds from sales of property, plant and equipment 0.00
Purchase of property, plant and equipment 3,486.00
Proceeds from sales of investment property 0.00
Purchase of investment property 0.00
Proceeds from sales of intangible assets 0.00
Purchase of intangible assets 0.00
Proceeds from sales of intangible assets under development 0.00
Purchase of intangible assets under development 0.00
Proceeds from sales of goodwill 0.00
Purchase of goodwill 0.00
Proceeds from biological assets other than bearer plants 0.00
Purchase of biological assets other than bearer plants 0.00
Proceeds from government grants 0.00
Proceeds from sales of other long-term assets 0.00
Purchase of other long-term assets 347.00
Cash advances and loans made to other parties 13,665.00
Cash receipts from repayment of advances and loans made to other parties 0.00
Cash payments for future contracts, forward contracts, option contracts and swap contracts 0.00
Cash receipts from future contracts, forward contracts, option contracts and swap contracts 0.00
Dividends received 0.00
Interest received 3,743.00
Income taxes paid (refund) 0.00
Other inflows (outflows) of cash 16,473.00
Net cash flows from (used in) investing activities (1,946.00)
Cash flows from used in financing activities
Proceeds from changes in ownership interests in subsidiaries 0.00
Payments from changes in ownership interests in subsidiaries 0.00
Proceeds from issuing shares 0.00
Proceeds from issuing other equity instruments 2,362.00
Payments to acquire or redeem entity's shares 0.00
Payments of other equity instruments 0.00
Proceeds from exercise of stock options 0.00
Proceeds from issuing debentures notes bonds etc 0.00
Proceeds from borrowings 203.00
Repayments of borrowings 2,449.00
Payments of lease liabilities 85.00
Dividends paid 0.00
Interest paid 613.00
Income taxes paid (refund) 0.00
Other inflows (outflows) of cash 318.00
Net cash flows from (used in) financing activities (264.00)
Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes (4,898.00)
Effect of exchange rate changes on cash and cash equivalents
Effect of exchange rate changes on cash and cash equivalents 0.00
Net increase (decrease) in cash and cash equivalents (4,898.00)
Cash and cash equivalents cash flow statement at beginning of period 8,120.00
Cash and cash equivalents cash flow statement at end of period 3,222.00





Details of Impact of Audit Qualification

Amount in (Lakhs)

Whether results are audited or unaudited Audited
Declaration of unmodified opinion or statement on impact of audit qualification Declaration of unmodified opinion
Auditor's opinion
Declaration pursuant to Regulation 33 (3) (d) of SEBI (LODR) Regulation, 2015: The company declares that its Statutory Auditor/s have issued an Audit Report with unmodified opinion for the period on Standalone results Yes
Sr No. Audit firm's name Whether the firm holds a valid peer review certificate issued by Peer Review Board of ICAI Certificate valid upto
1 M/s Pankaj R Shah & Associates Yes 31-10-2027


Statement on Deviation or Variation for proceeds of Public Issue, Rights Issue, Preferential Issue, Qualified Institutions Placement Etc. (1)

Amount in (Lakhs)

Mode of Fund Raising Public Issues
Description of mode of fund raising (Applicable in case of others is selected)
Date of Raising Funds 26-12-2024
Amount Raised 50,000.00
Report filed for Quarter ended 31-03-2026
Monitoring Agency Applicable
Monitoring Agency Name, if applicable CARE Ratings Limited
Is there a Deviation / Variation in use of funds raised No
If yes, whether the same is pursuant to change in terms of a contract or objects, which was approved by the shareholders
If Yes, Date of shareholder Approval
Explanation for the Deviation / Variation Not Applicable
Comments of the Audit Committee after review No Comments
Comments of the auditors, if any No Comments
Sr. Original Object Modified Object, if any Original Allocation Modified allocation, if any Funds Utilised Amount of Deviation/Variation for the quarter according to applicable object Remarks if any
1 Investment in one of our subsidiaries, Havix, to fund capital expenditure requirements for setting up a manufacturing facility for the production of sterile injections in our Atlanta Facility. Not Applicable 10,700.00 0.00 698.00 0.00 There is on-going delay in deployment of funds under object-1 to the extent of Rs. 33.02 crores as the company has utilized IPO proceeds of Rs. 6.98 crore against scheduled deployment of Rs. 40 crore in Fiscal 2026 due to ongoing geo-political issues. Hence, the company has taken management committee approval on March 03, 2026 to utilize the same by Fiscal 2027.
2 Re-payment/pre-payment, in full or in part, of certain borrowings availed by our Company Not Applicable 7,348.00 7,310.00 7,310.00 0.00 The unutilized amount of Rs. 0.38 crore has been transferred to GCP as resolved in the Board Meeting dated July 23, 2025.
3 Investment in our Subsidiary, namely, Havix, for re- payment/pre-payment in full or in part, of certain borrowings availed by such Subsidiaries Not Applicable 2,022.00 2,020.00 2,020.00 0.00 The unutilized amount of Rs. 0.02 crore has been transferred to GCP as resolved in the Board Meeting dated July 23, 2025.
4 Funding the working capital requirements of our Company Not Applicable 4,326.00 0.00 4,326.00 0.00 Utilized towards working capital by transferring to OD/CC accounts of SPL
5 Investment in our Subsidiaries, namely, SPI and Ratnatris to fund their working capital requirements Not Applicable 5,948.00 0.00 5,948.00 0.00 As per the PDF uploaded on the website of the Stock Exchange
6 Funding inorganic growth through acquisition and other strategic initiatives and general corporate purposes Not Applicable 15,437.00 16,107.00 15,716.00 0.00 Amount of Rs. 6.70 crore has been transferred from Objective 2, 3 and 7.
7 Offer expenses Not Applicable 4,219.00 3,588.00 3,480.00 0.00 The unutilized amount of Rs. 6.31 crore has been transferred to objective-6 as resolved in the Board Meeting dt. March 28, 2026.


Statement on Deviation or Variation for proceeds of Public Issue, Rights Issue, Preferential Issue, Qualified Institutions Placement Etc. (2)

Amount in (Lakhs)

Mode of Fund Raising Preferential Issues
Description of mode of fund raising (Applicable in case of others is selected)
Date of Raising Funds 28-03-2026
Amount Raised 9,500.00
Report filed for Quarter ended 31-03-2026
Monitoring Agency Not Applicable
Monitoring Agency Name, if applicable
Is there a Deviation / Variation in use of funds raised No
If yes, whether the same is pursuant to change in terms of a contract or objects, which was approved by the shareholders
If Yes, Date of shareholder Approval
Explanation for the Deviation / Variation false
Comments of the Audit Committee after review No Comments
Comments of the auditors, if any No Comments
Sr. Original Object Modified Object, if any Original Allocation Modified allocation, if any Funds Utilised Amount of Deviation/Variation for the quarter according to applicable object Remarks if any
1 Funding the working capital requirements of our Company Not Applicable 3,125.00 0.00 250.00 0.00
2 Funding the product development expenditure for the Company Not Applicable 2,500.00 0.00 0.00 0.00
3 Investment in our subsidiaries, by way of loan, to fund their working capital requirements Not Applicable 1,500.00 0.00 250.00 0.00
4 General Corporate Purpose Not Applicable 2,375.00 0.00 0.00 0.00


Signatory Details

Name of signatory Deval Rajnikant Shah
Designation of person Chief Financial Officer
Place Ahmedabad
Date 14-05-2026




Amount in (Lakhs)

Format for Disclosure of Related Party Transactions (applicable only for half-yearly filings i.e., 2nd and 4th quarter)

Sr No. Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.
Details of the party (listed entity/subsidiary) entering into the transaction Details of the counterparty Type of related party transaction Details of other related party transaction Value of the related party transaction as approved by the audit committee Remarks on approval by audit committee Value of the related party transaction ratified by the audit committee Date of Audit Committee Meeting where the ratification was approved Value of transaction during the reporting period In case monies are due to either party as a result of the transaction In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments Details of the loans, inter-corporate deposits, advances or investments Notes
Name PAN Name PAN Relationship of the counterparty with the listed entity or its subsidiary Opening balance Closing balance Nature of indebtedness (loan/ issuance of debt/ any other etc.) Details of other indebtedness Cost Tenure Nature (loan/ advance/ intercorporate deposit/ investment ) Interest Rate (%) Tenure Secured/ unsecured Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)
1 Senores Pharmaceuticals Ltd Aelius Projects LLP Enterprises over which Key Managerial Personnel and/or their Close relative exercise significant influence Any other transaction Rent Expense Approved 9.00 0.00 0.00
2 Senores Pharmaceuticals Ltd Espee Therapeutics LLP Enterprises over which Key Managerial Personnel and/or their Close relative exercise significant influence Any other transaction Reimbursement of Expenses Approved 11.00 2.00 9.00
3 Senores Pharmaceuticals Ltd Havix Group Inc Subsidiary Company Interest received Approved 271.00 257.00 429.00
4 Senores Pharmaceuticals Ltd Havix Group Inc Subsidiary Company Sale of goods or services Approved 1,182.00 721.00 1,627.00
5 Senores Pharmaceuticals Ltd Havix Group Inc Subsidiary Company Sale of goods or services Approved 381.00 770.00 1,148.00
6 Senores Pharmaceuticals Ltd Havix Group INC Subsidiary Company Any other transaction Recovery of expenses Approved 45.00 0.00 0.00
7 Senores Pharmaceuticals Ltd Havix Group INC Subsidiary Company Any other transaction Transfer of fixed asset Approved 1.00 0.00 0.00
8 Senores Pharmaceuticals Ltd Havix Group INC Subsidiary Company Loan Approved 331.00 372.00 750.00 Loan 9.00 Upto 7 years Unsecured Capex at Atlanta Facility
9 Senores Pharmaceuticals Ltd Havix Group INC Subsidiary Company Loan Approved 0.00 184.00 197.00 Loan 7.00 Upto 7 years Unsecured General Corporate Purposes
10 Senores Pharmaceuticals Ltd Havix Group INC Subsidiary Company Loan Approved 0.00 2,172.00 2,316.00 Loan 9.00 Upto 7 years Unsecured Repayment of Loans
11 Senores Pharmaceuticals Ltd Ratnatris Pharmaceuticals Private Limited Subsidiary Company Interest received Approved 148.00 241.00 389.00
12 Senores Pharmaceuticals Ltd Ratnatris Pharmaceuticals Private Limited Subsidiary Company Purchase of goods or services Approved 74.00 116.00 15.00
13 Senores Pharmaceuticals Ltd Ratnatris Pharmaceuticals Private Limited Subsidiary Company Loan Approved 70.00 1,991.00 467.00 Inter-corporate deposit 12.00 Repayable on Demand Unsecured Business Purpose
14 Senores Pharmaceuticals Ltd Ratnatris Pharmaceuticals Private Limited Subsidiary Company Loan Approved 724.00 1,076.00 1,792.00 Loan 12.00 Upto 7 years Unsecured General Corporate Purpose-repayment of Loans
15 Senores Pharmaceuticals Ltd Ratnatris Pharmaceuticals Private Limited Subsidiary Company Loan Approved 1,412.00 1,297.00 2,694.00 Loan 12.00 Upto 7 years Unsecured Working Capital
16 Senores Pharmaceuticals Ltd Ratnatris Pharmaceuticals Private Limited Subsidiary Company Any other transaction Recovery of Expenses Approved 70.00 0.00 6.00
17 Senores Pharmaceuticals Ltd Ratnatris Pharmaceuticals Private Limited Subsidiary Company Any other transaction Rent Expense Approved 1.00 0.00 0.00
18 Senores Pharmaceuticals Ltd Ratnatris Pharmaceuticals Private Limited Subsidiary Company Sale of goods or services Approved 217.00 283.00 149.00
19 Senores Pharmaceuticals Ltd Ratnatris Pharmaceuticals Private Limited Subsidiary Company Any other transaction Repayment of Borrowings (repayment of loan given) Approved 1,577.00 1,991.00 467.00
20 Senores Pharmaceuticals Ltd Remus Pharmaceuticals Limited Enterprises over which Key Managerial Personnel and/or their Close relative exercise significant influence Sale of goods or services Approved 124.00 100.00 73.00
21 Senores Pharmaceuticals Ltd Remus Pharmaceuticals Limited Enterprises over which Key Managerial Personnel and/or their Close relative exercise significant influence Any other transaction Recovery of expenses Approved 5.00 42.00 5.00
22 Senores Pharmaceuticals Ltd Remus Pharmaceuticals Limited Enterprises over which Key Managerial Personnel and/or their Close relative exercise significant influence Interest paid Approved 6.00 6.00 19.00
23 Senores Pharmaceuticals Ltd Renosen Pharmaceuticals Pvt Ltd. Enterprises over which Key Managerial Personnel and/or their Close relative exercise significant influence Any other transaction Consultancy Service Approved 15.00 5.00 5.00
24 Senores Pharmaceuticals Ltd Senores Pharmaceuticals Inc. Wholly owned Subsidiary company Interest received Approved 820.00 2,121.00 2,526.00
25 Senores Pharmaceuticals Ltd Senores Pharmaceuticals Inc. Wholly owned Subsidiary company Loan Approved 1,294.00 5,154.00 6,866.00 Loan 7.500 Upto 7 years Unsecured General Corporate Purpose
26 Senores Pharmaceuticals Ltd Senores Pharmaceuticals Inc. Wholly owned Subsidiary company Any other transaction Recovery of Expenses Approved 296.00 0.00 296.00
27 Senores Pharmaceuticals Ltd Senores Pharmaceuticals Inc. Wholly owned Subsidiary company Sale of goods or services Approved 1,040.00 1,168.00 2,049.00
28 Senores Pharmaceuticals Ltd Senores Pharmaceuticals Inc. Wholly owned Subsidiary company Investment Approved 0.00 3,251.00 3,251.00 Investment 0 Long Term Investment Unsecured Business Purpose Textual Information(1)
29 Senores Pharmaceuticals Ltd Swapnil Jatinbhai Shah Promoter and Key Managerial Personnel Any other transaction Remuneration to Directors Approved 563.00 225.00 38.00
30 Senores Pharmaceuticals Ltd Tapan Shah Close relatives of Key Managerial Personnel Any other transaction Consultancy Service Approved 2.00 0.00 0.00
31 Ratnatris Pharmaceuticals Pvt Ltd Babulal Misrimal Sanghavi Close relatives of Key Managerial Personnel Interest paid Approved 82.00 57.00 139.00
32 Ratnatris Pharmaceuticals Pvt Ltd Jitendra Babulal Sanghvi Promoter and Key Managerial Personnel Any other transaction Remuneration to Directors Approved 72.00 3.00 96.00
33 Ratnatris Pharmaceuticals Pvt Ltd Remus Pharmaceuticals Limited Enterprises over which Key Managerial Personnel and/or their Close relative exercise significant influence Interest paid Approved 25.00 14.00 39.00
34 Ratnatris Pharmaceuticals Pvt Ltd Remus Pharmaceuticals Limited Enterprises over which Key Managerial Personnel and/or their Close relative exercise significant influence Purchase of goods or services Approved 14.00 76.00 90.00
35 Ratnatris Pharmaceuticals Pvt Ltd Remus Pharmaceuticals Limited Enterprises over which Key Managerial Personnel and/or their Close relative exercise significant influence Sale of goods or services Approved 436.00 187.00 302.00
36 Ratnatris Pharmaceuticals Pvt Ltd Remus Pharmaceuticals Limited Enterprises over which Key Managerial Personnel and/or their Close relative exercise significant influence Sale of goods or services Approved 56.00 0.00 0.00
37 Havix Group Inc Senores Pharmaceuticals Inc. Fellow Subsidiary Sale of goods or services Approved 1,841.00 881.00 1,362.00
38 Havix Group Inc Ashokbhai Vijaysinh Barot Key Managerial Personnel Any other transaction Remuneration to Directors Approved 23.00 0.00 0.00
39 Senores Pharmaceuticals Ltd Aelius Projects LLP Enterprises over which Key Managerial Personnel and/or their Close relative exercise significant influence Any other transaction Outstanding Balances-Trade Payable Approved 0.00 2.00 3.00
40 Senores Pharmaceuticals Ltd Espee Pharma UK Ltd Enterprises over which Key Managerial Personnel and/or their Close relative exercise significant influence Any other transaction Outstanding Balances-Trade Payable Approved 0.00 1.00 1.00
41 Senores Pharmaceuticals Ltd Espee Therapeutics LLP Enterprises over which Key Managerial Personnel and/or their Close relative exercise significant influence Any other transaction Outstanding Balances-Trade Receivable Approved 0.00 2.00 0.00
42 Senores Pharmaceuticals Ltd Havix Group INC Subsidiary company Any other transaction Outstanding Balances-Non Current investments Approved 0.00 7,339.00 7,339.00
43 Senores Pharmaceuticals Ltd Havix Group INC Subsidiary company Any other transaction Outstanding Balances-Loans & Advances Approved 0.00 4,780.00 6,290.00
44 Senores Pharmaceuticals Ltd Havix Group INC Subsidiary company Any other transaction Outstanding Balances-Trade Receivable Approved 0.00 1,490.00 2,775.00
45 Senores Pharmaceuticals Ltd Ratnatris Pharmaceuticals Private Limited Subsidiary company Any other transaction Outstanding Balances-Non Current investments Approved 0.00 2,842.00 2,842.00
46 Senores Pharmaceuticals Ltd Ratnatris Pharmaceuticals Private Limited Subsidiary company Any other transaction Outstanding Balances-Trade Receivable Approved 0.00 283.00 155.00
47 Senores Pharmaceuticals Ltd Ratnatris Pharmaceuticals Private Limited Subsidiary company Any other transaction Outstanding Balances-Loans & Advances to (Including Interest and Net of TDS Receivable) Approved 0.00 4,604.00 5,342.00
48 Senores Pharmaceuticals Ltd Ratnatris Pharmaceuticals Private Limited Subsidiary company Any other transaction Outstanding Balances-Trade Payable Approved 0.00 116.00 131.00
49 Senores Pharmaceuticals Ltd Remus Pharmaceuticals Limited Enterprises over which Key Managerial Personnel and/or their Close relative exercise significant influence Any other transaction Outstanding Balances-Trade Receivable Approved 0.00 143.00 78.00
50 Senores Pharmaceuticals Ltd Remus Pharmaceuticals Limited Enterprises over which Key Managerial Personnel and/or their Close relative exercise significant influence Any other transaction Outstanding Balances-Borrowings Approved 0.00 157.00 169.00
51 Senores Pharmaceuticals Ltd Renosen Pharmaceuticals Pvt Ltd. Enterprises over which Key Managerial Personnel and/or their Close relative exercise significant influence Any other transaction Outstanding Balances-Trade Payable Approved 0.00 3.00 5.00
52 Senores Pharmaceuticals Ltd Senores Pharmaceuticals Inc. Wholly owned Subsidiary company Any other transaction Outstanding Balances-Non Current investments Approved 0.00 3,773.00 3,773.00
53 Senores Pharmaceuticals Ltd Senores Pharmaceuticals Inc. Wholly owned Subsidiary company Any other transaction Outstanding Balances-Trade Receivable Approved 0.00 1,168.00 2,346.00
54 Senores Pharmaceuticals Ltd Senores Pharmaceuticals Inc. Wholly owned Subsidiary company Any other transaction Outstanding Balances-Loans & Advances Approved 0.00 19,342.00 22,255.00
55 Senores Pharmaceuticals Ltd Swapnil Jatinbhai Shah Promoter and Key Managerial Personnel Any other transaction Outstanding Balances-Payable on Employee benefits Approved 0.00 225.00 38.00
56 Ratnatris Pharmaceuticals Pvt Ltd Adroit Life Science Private Limited Enterprises over which Key Managerial Personnel and/or their Close relative exercise significant influence Any other transaction Outstanding Balances-Trade Receivables Approved 0.00 41.00 260.00
57 Ratnatris Pharmaceuticals Pvt Ltd Babulal Misrimal Sanghavi Close relatives of Key Managerial Personnel Any other transaction Outstanding Balances-Interest payable Approved 0.00 57.00 125.00
58 Ratnatris Pharmaceuticals Pvt Ltd Babulal Misrimal Sanghavi Close relatives of Key Managerial Personnel Any other transaction Outstanding Balances-Borrowings Approved 0.00 1,562.00 1,122.00
59 Ratnatris Pharmaceuticals Pvt Ltd Jitendra Babulal Sanghvi Promoter and Key Managerial Personnel Any other transaction Outstanding Balances-Payables for employee benefits Approved 0.00 3.00 6.00
60 Ratnatris Pharmaceuticals Pvt Ltd Remus Pharmaceuticals Limited Enterprises over which Key Managerial Personnel and/or their Close relative exercise significant influence Any other transaction Outstanding Balances-Interest payable Approved 0.00 14.00 39.00
61 Ratnatris Pharmaceuticals Pvt Ltd Remus Pharmaceuticals Limited Enterprises over which Key Managerial Personnel and/or their Close relative exercise significant influence Any other transaction Outstanding Balances-Borrowings Approved 0.00 486.00 482.00
62 Ratnatris Pharmaceuticals Pvt Ltd Remus Pharmaceuticals Limited Enterprises over which Key Managerial Personnel and/or their Close relative exercise significant influence Any other transaction Outstanding Balances-Trade Receivable Approved 0.00 111.00 212.00
63 Ratnatris Pharmaceuticals Pvt Ltd Renosen Pharmaceuticals Pvt Ltd. Enterprises over which Key Managerial Personnel and/or their Close relative exercise significant influence Any other transaction Outstanding Balances-Trade Receivable Approved 0.00 2.00 59.00
64 Havix Group Inc Senores Pharmaceuticals Inc. Fellow Subsidiary Any other transaction Outstanding Balances-Trade Payable Approved 0.00 4,549.00 4,804.00
65 Senores Pharmaceuticals Ltd Espee Therapeutics LLP Enterprises over which Key Managerial Personnel and/or their Close relative exercise significant influence Any other transaction Outstanding Balances-Trade Payable Approved 0.00 0.00 9.00
66 Senores Pharmaceuticals Ltd Apnar Pharma Private Limited Subsidiary Company Sale of goods or services Approved 1.00 0.00 0.00
67 Senores Pharmaceuticals Ltd Apnar Pharma Private Limited Subsidiary Company Any other transaction Transfer of fixed asset Approved 1.00 0.00 0.00
68 Senores Pharmaceuticals Ltd Apnar Pharma Private Limited Subsidiary Company Loan Approved 2,206.00 0.00 2,206.00
69 Senores Pharmaceuticals Ltd Apnar Pharma Private Limited Subsidiary Company Interest received Approved 28.00 0.00 26.00
70 Senores Pharmaceuticals Ltd Apnar Pharma Private Limited Subsidiary Company Any other transaction Outstanding Balances-Trade Receivable Approved 0.00 0.00 3.00
71 Senores Pharmaceuticals Ltd Apnar Pharma Private Limited Subsidiary Company Investment Approved 1,146.00 0.00 0.00
72 Senores Pharmaceuticals Ltd Ratnatris Pharmaceuticals Private Limited Subsidiary Company Any other transaction Purchase of fixed asset Approved 90.00 0.00 108.00
73 Senores Pharmaceuticals Ltd Remus Pharmaceuticals Limited Enterprises over which Key Managerial Personnel and/or their Close relative exercise significant influence Any other transaction Purchase of fixed asset Approved 88.00 0.00 0.00
74 Senores Pharmaceuticals Ltd SENORES FOUNDATION Enterprises over which Key Managerial Personnel and/or their Close relative exercise significant influence Investment Approved 0.00 0.00 0.00
75 Senores Pharmaceuticals Ltd SENORES FOUNDATION Enterprises over which Key Managerial Personnel and/or their Close relative exercise significant influence Any other transaction Outstanding Balances-Non Current investments Approved 0.00 0.00 0.00
76 Senores Pharmaceuticals Ltd Senores Biologics Private Limited Enterprises over which Key Managerial Personnel and/or their Close relative exercise significant influence Sale of goods or services Approved 1.00 0.00 1.00
77 Senores Pharmaceuticals Ltd Senores Biologics Private Limited Enterprises over which Key Managerial Personnel and/or their Close relative exercise significant influence Any other transaction Recovery of expenses Approved 31.00 0.00 31.00
78 Senores Pharmaceuticals Ltd Senores Biologics Private Limited Enterprises over which Key Managerial Personnel and/or their Close relative exercise significant influence Any other transaction Outstanding Balances-Trade Receivable Approved 0.00 0.00 33.00
79 Senores Pharmaceuticals Ltd Havix Group Inc Subsidiary Company Loan Approved 641.00 1,794.00 2,598.00
80 Senores Pharmaceuticals Ltd Aelius Projects LLP Enterprises over which Key Managerial Personnel and/or their Close relative exercise significant influence Any other transaction Outstanding Balances-Trade Receivable Approved 0.00 1.00 1.00
81 Senores Pharmaceuticals Ltd Ratnatris Pharmaceuticals Private Limited Subsidiary Company Any other transaction Corporate Gurantee Commission Expense Approved 7.00 0.00 7.00
82 Senores Pharmaceuticals Inc Apnar Pharma Private Limited Fellow Subsidiary Any other transaction Recovery of expenses Approved 115.00 0.00 0.00
83 Senores Pharmaceuticals Inc Apnar Pharma Private Limited Fellow Subsidiary Any other transaction Outstanding Balances-Trade Receivable Approved 0.00 0.00 121.00
84 Havix Group Inc Apnar Pharma Private Limited Fellow Subsidiary Purchase of goods or services Approved 89.00 0.00 89.00
85 Havix Group Inc Apnar Pharma Private Limited Fellow Subsidiary Purchase of goods or services Approved 96.00 0.00 96.00
86 Havix Group Inc Senores Pharmaceuticals Inc. Fellow Subsidiary Sale of goods or services Approved 144.00 0.00 0.00
87 Havix Group Inc Senores Pharmaceuticals Inc. Fellow Subsidiary Any other transaction Outstanding Balances-Trade Receivable Approved 0.00 0.00 1,362.00
88 Apnar Pharma Private Limited Swapnil Patel Promoter and Key Managerial Personnel Any other transaction Remuneration to Directors Approved 12.00 0.00 0.00
89 Apnar Pharma Private Limited Senores Biologics Private Limited Enterprises over which Key Managerial Personnel and/or their Close relative exercise significant influence Investment Approved 55.00 0.00 55.00
Total value of transaction during the reporting period 17,989.00



Text Block

Textual Information(1) Investment in Equity shares